Abstract: Systems, apparatuses, and methods are taught that provide assistance to a user through an eyewear device. Data is received from a first sensor. The first sensor is incorporated into an eyewear device. The first sensor measures a parameter related to the user. A state of the user is analyzed using the data. Assistance is provided to the user. The assistance is in a form of feedback, and the feedback is related to the state of the user. The assistance can also be related to a context of the user and a state of the user. The context of the user is determined from the data.

Abstract: Systems, apparatuses, and methods are taught that provide reconfigurable components for eyewear devices. A reconfigurable component for use in an eyewear device includes an embedded electronics system. The embedded electronics system is configured for wireless communication and for processing sensor signals. The embedded electronics system is embedded into a component of the eyewear device. A plurality of sensors is embedded into one or more of the reconfigurable component and the eyewear device. The plurality is in electrical communication with the embedded electronics system. The embedded electronic system further includes a processor. The processor is configured to receive outputs from the plurality of sensors and to determine a system control parameter from an output of at least one sensor of the plurality of sensors.

Abstract: Disclosed herein are genetically modified T-cells and CAR-T cells that have an increased ability to process the essential amino acid arginine, for example, by overexpressing amino acid transporters, particularly arginine transporters. Such genetically modified T-cells and CAR-T cells can better survive the often hostile tumor microenvironment because of their increased ability to process arginine. The methods and compositions described here are used to augment the amount of arginine available to a T-cell. The methods and compositions described herein are also used to augment the amount of arginine available to a CAR-T-cell, thus providing a CAR-T cell that can be effective in the treatment of solid tumors by surviving the tumor microenvironment.

Abstract: Provided are use of an arginase (e.g., a non-PEGylated arginase or a PEGylated arginase) in the treatment of viral-associated diseases or disorders, use of arginase in the treatment of other pathogen-associated diseases or disorders, and kits comprising arginase for said uses.